Nov 03, 2021
Aetna launched a national network for members to access new therapies for rare genetic diseases. Beginning January 1, 2022, the Gene-based, Cellular, and Other Innovative Therapies (GCIT) network will provide three gene therapy services for inherited retinal disease and spinal muscular atrophy. The network is included as a standard medical benefit in all Aetna fully insured plans and is available to self-insured plans.
The network includes more than 75 designated GCIT service providers that have demonstrated quality and value. A dedicated clinical team guides members and providers through the health care process, including case management, where applicable, and travel and lodging support for members who need to travel 100 miles or more for care.
The GCIT network offers a financial protection program for CVS Caremark clients and Aetna plan sponsors who do not have traditional stop-loss.
"Our multi-pronged approach encompasses safety, member access to cutting-edge therapies, and cost management…It also paves the way for future FDA-approved gene therapies to be added quickly and cost-effectively," said Richard Gentleman, Executive Director, National Partner Strategy, Aetna.
